The effectiveness of EMDR vs EMDR 2.0 vs the Flash technique in the treatment of patients with PTSD: A Randomized Controlled Trial

Conditions: Traumagerelateerde stoornissen
PTSD Posttraumatic Stress Disorder
Trauma
10002861

Registration Number: NL-OMON54264

Lead Sponsor: niversiteit Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 130

Inclusion Criteria

Estimated IQ > 80
PTSD diagnosis according to the DSM-5
18 years or older
Sufficient understanding of the Dutch language

Exclusion Criteria

Acute suicidality
PTSD diagnosis not the primary diagnosis
Changes in medication during, or 6 weeks prior to participation in the research
Use of strongly sedating medication

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary dependent variables for measuring the effectiveness of the<br /><br>treatment are the presence of the diagnosis PTSD (CAPS-5) and complex PTSD<br /><br>(ITQ) and the severity of PTSD symptoms (PCL-5, CAPS-5, ITQ). The CAPS-5 and<br /><br>ITQ are administered before treatment and four and twelve weeks after<br /><br>termination of treatment. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>De secondary dependent variables for measuring the effectiveness of treatment<br /><br>are depressive, dissociative and general psychiatric symptoms (BDI, DES and BSI<br /><br>respectively) and experiential avoidance (AAQ-II). The dependent variables for<br /><br>measuring treatment efficiency are amount of treated targets per session and<br /><br>duration of each session. The dependent variables for measuring treatment<br /><br>acceptability are four open questions about treatment acceptability with answer<br /><br>options rated on a 7-point scale. Safety of the intervention will be measured<br /><br>with the amount of serious aversive events (SAEs). The PCL-5, BDI, BSI and<br /><br>AAQ-II will be adminstered weekly during the treatment period and biweekly<br /><br>until 12 weeks after termination of treatment. The treatment acceptability<br /><br>questionnaire will be adminstered after the first and final treatment session. </p><br>